Kidney cancer study questions need for surgery in advanced cases
NCT ID NCT00930033
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial tested whether removing the kidney (nephrectomy) before taking the drug sunitinib helps people with metastatic kidney cancer live longer compared to taking sunitinib alone. 452 patients were randomly assigned to either surgery plus sunitinib or sunitinib only. The main goal was to see if adding surgery improved overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sunitinib
- What this could lead to
- If successful, this could show that skipping surgery and using only sunitinib is just as effective, sparing patients from an invasive procedure.
- What could go wrong
- This trial is already completed, so results are known. The study may not apply to all kidney cancer types, and sunitinib has side effects like fatigue and high blood pressure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hopital Necker
Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- Radiation boosts immunotherapy in kidney cancer trial
- Immunotherapy duo shows promise in kidney cancer battle
- Brain cancer trial halted early: can Memory-Sparing radiation help when tumors return?
- Folic acid may soothe cancer treatment side effects